Pravastatin ( DrugBank: Pravastatin )


9 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎1
46悪性関節リウマチ3
49全身性エリテマトーデス1
67多発性嚢胞腎3
79家族性高コレステロール血症(ホモ接合体)1
96クローン病1
164眼皮膚白皮症1
265脂肪萎縮症3
333ハッチンソン・ギルフォード症候群3

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00200655
(ClinicalTrials.gov)
December 200412/9/2005Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple SclerosisSafety and Efficacy of Pravastatin in Relapsing-remitting MS: a Double Blind Placebo Controlled StudyRelapsing-remitting Multiple SclerosisDrug: Pravastatin;Drug: PlaceboNantes University HospitalNULLCompleted18 Years45 YearsBoth40Phase 3France

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04608344
(ClinicalTrials.gov)
November 4, 202023/10/2020Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsA Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsRheumatoid ArthritisDrug: Atorvastatin;Drug: Pravastatin;Drug: Rosuvastatin;Drug: FilgotinibGilead SciencesGalapagos NVCompleted18 Years55 YearsAll27Phase 1United States
2NCT03131973
(ClinicalTrials.gov)
May 13, 201725/4/2017Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinEffects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy ParticipantsRheumatoid ArthritisDrug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: PravastatinBristol-Myers SquibbNULLCompleted18 Years50 YearsAll26Phase 1United States
3NCT02456844
(ClinicalTrials.gov)
May 201527/5/2015Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy PatientsEffects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy SubjectsRheumatoid ArthritisDrug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, Leucovorin and BMS-986142Bristol-Myers SquibbNULLCompleted18 Years50 YearsBoth24Phase 1NULL

49. 全身性エリテマトーデス


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 198
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00054938
(ClinicalTrials.gov)
March 200313/2/2003Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)A Randomized Controlled Trial of Strategies for the Prevention of Accelerated Atherosclerosis in Systemic Lupus Erythematosus - A Pilot StudySystemic Lupus Erythematosus;LupusDrug: pravastatin;Drug: aspirin;Drug: ramipril;Drug: Vitamins: B6, B12, and folate;Behavioral: heart health educational programBrigham and Women's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed18 YearsN/ABoth150Phase 2United States

67. 多発性嚢胞腎


臨床試験数 : 216 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 150
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04284657
(ClinicalTrials.gov)
January 30, 201911/4/2019Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseasePravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney DiseaseDrug: Pravastatin;Drug: sodium citrateUniversity of Southern CaliforniaNULLEnrolling by invitation18 YearsN/AAll30Phase 2United States
2NCT03273413
(ClinicalTrials.gov)
August 31, 20171/9/2017Statin Therapy in Patients With Early Stage ADPKDStatin Therapy in Patients With Early Stage ADPKDADPKD;Autosomal Dominant Polycystic KidneyDrug: Pravastatin;Drug: PlaceboUniversity of Colorado, DenverNULLRecruiting25 Years60 YearsAll200Phase 4United States
3NCT00456365
(ClinicalTrials.gov)
November 200612/3/2007Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney DiseasePolycystic Kidney, Autosomal DominantDrug: pravastatin;Drug: PlaceboUniversity of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed8 Years22 YearsAll110Phase 3United States

79. 家族性高コレステロール血症(ホモ接合体)


臨床試験数 : 142 薬物数 : 114 - (DrugBank : 29) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 18
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03510715
(ClinicalTrials.gov)
August 31, 201818/4/2018An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: LovastatinSanofiRegeneron PharmaceuticalsCompleted8 Years17 YearsAll18Phase 3Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States

96. クローン病


臨床試験数 : 2,400 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 168 - 標的パスウェイ数 : 214
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00599625
(ClinicalTrials.gov)
October 200426/12/2007Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot StudyPravastatin Therapy in Patients With Active Crohn's Disease: A Pilot StudyCrohn's DiseaseDrug: PravastatinUniversity of VirginiaAmerican College of GastroenterologyRecruiting18 Years65 YearsBoth40N/AUnited States

164. 眼皮膚白皮症


臨床試験数 : 15 薬物数 : 57 - (DrugBank : 34) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 138
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00467831
(ClinicalTrials.gov)
April 200728/4/2007Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak SyndromePilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak SyndromeHermansky-Pudlak Syndrome (HPS);Pulmonary Fibrosis;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Metabolic DiseaseDrug: Losartan;Drug: Zileuton;Drug: N-Acetylcysteine;Drug: Pravastatin;Drug: ErythromycinNational Human Genome Research Institute (NHGRI)NULLTerminated18 Years70 YearsAll3Phase 1/Phase 2United States

265. 脂肪萎縮症


臨床試験数 : 116 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00227500
(ClinicalTrials.gov)
July 200127/9/2005Pravastatin for Hyperlipidaemia in HIV.A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIVHIV Infections;Lipid Metabolism;Glucose Metabolism;Metabolic Abnormality;Lipodystrophy;Cardiovascular DiseaseDrug: PravastatinKirby InstituteThe University of New South Wales;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;St Vincent's Hospital, SydneyCompleted18 YearsN/ABoth40Phase 4Australia
2NCT00017758
(ClinicalTrials.gov)
June 200111/6/2001The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering DrugsThe Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase InhibitorsHIV Infections;HIV Seronegativity;LipodystrophyDrug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: EfavirenzNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years60 YearsBoth56Phase 1United States
3NCT00006412
(ClinicalTrials.gov)
October 25, 200013/10/2000Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood LipidsA Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid AbnormalitiesHIV Infections;LipodystrophyDrug: Pravastatin sodium;Drug: FenofibrateNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 YearsN/AAll630Phase 3United States;Puerto Rico

333. ハッチンソン・ギルフォード症候群


臨床試験数 : 7 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00916747
(ClinicalTrials.gov)
August 20095/6/2009Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaAn Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid LaminopathiesProgeriaDrug: Lonafarnib, Zoledronic Acid, and PravastatinBoston Children's HospitalSchering-Plough;Merck Sharp & Dohme Corp.;Eiger BioPharmaceuticalsActive, not recruitingN/AN/AAll85Phase 2United States
2NCT00879034
(ClinicalTrials.gov)
March 20098/4/2009A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaA Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: Lonafarnib;Drug: Zoledronic Acid;Drug: PravastatinBoston Children's HospitalDana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-PloughCompletedN/AN/AAll5Phase 2United States
3NCT00731016
(ClinicalTrials.gov)
October 20081/8/2008Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic AcidTreatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic AcidHutchinson-Gilford Progeria SyndromeDrug: Zoledronic acid, pravastatinAssistance Publique Hopitaux De MarseilleNULLCompleted3 YearsN/ABoth15Phase 2France